HHLR Advisors’s Pacific Biosciences PACB Stock Holding History

HHLR Advisors’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.54M	Hold	918,892	–	–	0.19%	28
2026 Q1	$1.21M	Hold	918,892	–	–	0.07%	25
2025 Q4	$1.72M	Hold	918,892	–	–	0.06%	24
2025 Q3	$1.18M	Hold	918,892	–	–	0.03%	28
2025 Q2	$1.14M	Hold	918,892	–	–	0.04%	32
2025 Q1	$1.08M	Hold	918,892	–	–	0.03%	41
2024 Q4	$1.68M	Hold	918,892	–	–	0.06%	37
2024 Q3	$1.56M	Hold	918,892	–	–	0.03%	38
2024 Q2	$1.26M	Hold	918,892	–	–	0.03%	68
2024 Q1	$3.45M	Hold	918,892	–	–	0.07%	39
2023 Q4	$9.01M	Hold	918,892	–	–	0.18%	30
2023 Q3	$7.67M	Buy	+918,892	New	+$10.5M	0.17%	39
2021 Q4	–	Sell	-911,039	Closed	-$23.3M	–	85
2021 Q3	$23.3M	Buy	+911,039	New	+$27M	0.3%	42

Other funds holding PACB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

HHLR Advisors's PACB Position: Q2 2026 in Review

HHLR Advisors held its Pacific Biosciences (PACB) position steady in Q2 2026 at 918,892 shares worth $1.54M. The position accounts for 0.19% of the portfolio, ranked #28.

HHLR Advisors first reported a position in PACB in Q3 2021 and has held it in 13 quarters since. The position peaked at $23.3M in Q3 2021. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

HHLR Advisors held 918,892 shares of Pacific Biosciences worth $1.54M as of Q2 2026.
HHLR Advisors left its Pacific Biosciences share count unchanged in Q2 2026.
Pacific Biosciences made up 0.19% of HHLR Advisors's portfolio in Q2 2026, its #28 holding.
HHLR Advisors first reported a position in Pacific Biosciences in Q3 2021 and has held it in 13 quarters since.
HHLR Advisors's Pacific Biosciences position peaked at $23.3M in Q3 2021.
223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on HHLR Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.